BASIS研究:marstacimab预防治疗中突破性出血与手术管理
BASIS三期研究纳入116例无抑制物的重型血友病A或中重度至重型血友病B患者,在12个月主动治疗期接受marstacimab预防治疗。75例(64.7%)发生453次急性突破性出血并接受因子替代治疗,83%单次输注即控制。15例手术中86.7%未中断marstacimab,无血栓栓塞事件。
要点
- 突破性出血多可单次因子替代治疗控制(83%)
- 小手术可不停marstacimab,因子使用与其他非因子预防药相当
- 大手术数据缺乏,结论仅限小手术和牙科操作
核心结论
- 突破性出血通常经标准因子替代治疗控制,多数仅需1次输注。
- 小手术围术期管理可不中断marstacimab,因子替代使用与其他非因子预防药相当。
研究设计与样本
- BASIS三期研究:6个月观察期后,116例无抑制物血友病A或B患者接受marstacimab 300 mg负荷后150 mg每周一次,共12个月主动治疗期。
- 因样本量小和事件分布,出血发生率、因子替代治疗使用和围术期管理采用描述性分析。
主要发现
- 116例中75例(64.7%)发生453次急性突破性出血并接受因子替代治疗。
- 83%的突破性出血经单次输注控制,最常用标准半衰期重组或血浆源性凝血因子VIII/IX。
- 13例患者接受15次操作(8次牙科、7次其他),86.7%继续marstacimab,15次中13次(86.7%)使用因子替代治疗。
- 主动治疗期无血栓栓塞事件发生。
临床怎么用
- marstacimab预防治疗中突破性出血可首选标准半衰期因子替代治疗,多数单次输注可控制。
- 小手术和牙科操作围术期可继续marstacimab,按需使用因子替代治疗。
- 大手术因研究排除缺乏数据,高风险操作围术期方案需进一步研究。
局限性
- 样本量小且事件分布有限,分析为描述性。
- 研究排除大手术,结论仅限小手术和牙科操作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Marstacimab, a subcutaneous antitissue factor pathway inhibitor monoclonal antibody, has demonstrated efficacy in reducing treated bleeds in severe hemophilia A or moderately severe to severe hemophilia B without inhibitors in the phase 3 BASIS study. Evidence guiding management of breakthrough bleeds and perioperative hemostasis during marstacimab prophylaxis remains limited. OBJECTIVES: Describe the frequency, treatment, and outcomes of breakthrough bleeds and surgical/medical procedures in participants without inhibitors receiving marstacimab prophylaxis. METHODS: After the 6-month observation phase, participants received a 300 mg marstacimab loading dose followed by 150 mg once-weekly in a 12-month active treatment phase (ATP). Bleed incidence, factor replacement therapy (FRT) use, and perioperative management were analyzed descriptively due to the small sample size and event distribution RESULTS: Of 116 participants in the ATP, 75 (64.7%) experienced 453 acute breakthrough bleeds and were treated with FRT; 83% were controlled with a single infusion, most often standard half-life recombinant or plasma-derived factor VIII/IX. Thirteen participants underwent 15 procedures (8 dental and 7 other), with marstacimab continued in 86.7% and FRT used in 13 of 15 (86.7%). No thromboembolic events occurred during ATP. CONCLUSION: Breakthrough bleeds were generally controlled with standard FRT, with most requiring only 1 infusion. Perioperative management of minor procedures was feasible without interruption of marstacimab, with FRT use comparable with other nonfactor prophylactic agents. Data on major surgery are lacking due to study exclusions, and conclusions should be restricted to minor and dental procedures. Further studies are needed to define perioperative protocols for higher-risk interventions.
引用
- Mahlangu J, Matino D, Benítez Hidalgo O, et al. Management of breakthrough bleeds and surgical procedures in participants with hemophilia A or B without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study. J Thromb Haemost. 2026. PMID: 42107711. doi:10.1016/j.jtha.2026.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。